Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

Weight gain is a major adverse effect of several second-generation antipsychotic medications. Rimonabant is a cannabinoid-1 receptor antagonist that promotes weight loss in the general population. We conducted a 16-week, double-blind, placebo-controlled study of rimonabant (20 mg/d) in people with s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kelly, Deanna L., Gorelick, David A., Conley, Robert R., Boggs, Douglas L., Linthicum, Jared, Liu, Fang, Feldman, Stephanie, Ball, M. Patricia, Wehring, Heidi J., McMahon, Robert P., Huestis, Marilyn A., Heishman, Stephen J., Warren, Kimberly R., Buchanan, Robert W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717343/
https://ncbi.nlm.nih.gov/pubmed/21192149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0b013e318204825b
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados